Original Research
This study was conducted to determine the efficacy and safety of three once-weekly injections of intra-articular Hylan G-F 20 in patients with chronic knee osteoarthritis over 26 weeks. It was hypothesized that Hylan G-F 20 would provide significant pain relief with no increased safety risk compared with IA saline (placebo).
Corrigendum
The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R, Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. Drugs Context. 2024;13:2023-8-1. https://doi.org/10.7573/dic.2023-8-1
Original Research
This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal.
Review
This article aims to review the literature on mechanisms of post-contrast acute kidney injury, risk factors and available strategies to control the risk in patients with cancer and to report the authors’ experience with managing post-contrast acute kidney injury risk in oncology.
Case Series
This collection of clinical experiences focuses on patients on siltuximab therapy, particularly regarding the idiopathic multicentric Castleman disease (iMCD) diagnostic work-up and treatment administration in patients with complex disease entering differential diagnosis with Castleman disease or with concomitant diseases.
